ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Glioma targeted therapy: insight into future of molecular approaches

Yang, Keyang; Wu, Zhijing; Zhang, Hao; Zhang, Nan; Wu, Wantao; Wang, Zeyu; Dai, Ziyu; Zhang, Xun; Zhang, Liyang; Peng, Yun; Ye, Weijie; Zeng, Wenjing; Liu, Zhixiong*; Cheng, Quan*哈尔滨医科大学
Molecular Cancer2022-2-8DOI: 10.1186/s12943-022-01513-z
236被引5阅读
引用收藏
分享

摘要

Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically, gliomas occur among all ages, more often seen in adults, which males are more susceptible than females. According to the fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), standard of care and prognosis of gliomas can be dramatically different. Generally, circumscribed gliomas are usually benign and recommended to early complete resection, with chemotherapy if necessary. Diffuse gliomas and other high-grade gliomas according to their molecule subtype are slightly intractable, with necessity of chemotherapy. However, for glioblastoma, feasible resection followed by radiotherapy plus temozolomide chemotherapy define the current standard of care. Here, we discuss novel feasible or potential targets for treatment of gliomas, especially IDH-wild type glioblastoma. Classic targets such as the p53 and retinoblastoma (RB) pathway and epidermal growth factor receptor (EGFR) gene alteration have met failure due to complex regulatory network. There is ever-increasing interest in immunotherapy (immune checkpoint molecule, tumor associated macrophage, dendritic cell vaccine, CAR-T), tumor microenvironment, and combination of several efficacious methods. With many targeted therapy options emerging, biomarkers guiding the prescription of a particular targeted therapy are also attractive. More pre-clinical and clinical trials are urgently needed to explore and evaluate the feasibility of targeted therapy with the corresponding biomarkers for effective personalized treatment options.

学科与关键词

关键词
NEWLY-DIAGNOSED GLIOBLASTOMAPHASE-II TRIALLOW-GRADE GLIOMACENTRAL-NERVOUS-SYSTEMRECURRENT MALIGNANT GLIOMAT-CELL-ACTIVATIONINTEGRIN-ASSOCIATED PROTEINGENE PROMOTER METHYLATIONTYROSINE KINASE INHIBITORSINGLE-AGENT BEVACIZUMAB
相关
加载中…
  • Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
    Lan, Zhong; Li, Xin; Zhang, XiaoqinINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25(5).
  • DNA Repair Mechanisms and Therapeutic Targets in Glioma
    Elmore, Kevin B.; Schaff, Lauren R.*CURRENT ONCOLOGY REPORTS, SPRINGER, ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES, 87, 2021-08.
  • Current Immunotherapies for Glioblastoma Multiforme
    Huang, Boyuan; Li, Xuesong; Li, Yuntao; Zhang, Jin; Zong, Zhitao*; Zhang, Hongbo*Frontiers in Immunology, 2021, 11: 603911.被引 63
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Cancer
发表日期
2022-02-08
卷期
第 21 卷, 第 1 期
页码
39
DOI
10.1186/s12943-022-01513-z
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82073893, 82172685, 81873635, 81703622]; China Postdoctoral Science Foundation [2018M633002]; Hunan Provincial Natural Science Foundation of China [2018SK2101, 2018JJ3838]; Hunan Provincial Health Committee Foundation of China [C2019186]; Xiangya Hospital Central South University postdoctoral foundation

作者

  • Y

    Yang, Keyang (第一作者)

  • W

    Wu, Zhijing

查看全部 14 位作者收起作者
  • Z

    Zhang, Hao

  • Z

    Zhang, Nan

    harbin med univ

  • W

    Wu, Wantao

  • W

    Wang, Zeyu

  • D

    Dai, Ziyu

  • Z

    Zhang, Xun

  • Z

    Zhang, Liyang

  • P

    Peng, Yun

  • Y

    Ye, Weijie

  • Z

    Zeng, Wenjing

  • L

    Liu, Zhixiong (通讯)

  • C

    Cheng, Quan (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417